Abstract Recent paradigm in the field of cancer defines its origin from a small population of fast-growing cells known as cancer stem cells (CSCs), and they are mainly responsible for disease aggressiveness, drug resistance, and tumor relapse. The existence of CSCs has been proven in different types of cancer and possesses characteristic expression of a wide array of cell surface markers specific to the type of cancer. CSCs have been isolated and enriched using several surface markers in different cancer types. Self-renewal, drug resistance, and the ability to transition from epithelial to mesenchymal phenotype are the major features attributed to this fraction of mutated stem cells. The CSC hypothesis proposes that these CSCs mimic stem cells by sharing similar pathways, such as Wnt, SHH, Notch, and others. Further, the niche, which in this case is the tumor microenvironment, plays a very important role in the maintenance of CSCs. Altogether, this emerging field of research on CSCs is expected to unveil answers to the most difficult issues of one of the most dreadful diseases called cancer.
Introduction
Cancer has been prevailing in this world for several years devouring the lives of millions of people. It has been estimated that in the current year, 1,638,910 new cases and 577,190 deaths would result due to cancer solely in the USA [1] . There are approximately 2,650,000 articles in the NCBI database addressing different aspects of cancer. Despite extensive research going on in this malignant disease, no definitive treatment has yet been identified till date. This is due to the fact that cancer targets are difficult to study since it is controlled by an array of signaling events. Recent insights into cancer biology have uncovered several potential players responsible for this disease. The recent focus of many laboratories is cancer stem cells (CSCs) due to its prevalence in most of the cancer prone tissues such as breast, pancreas, prostate, leukemia, ovary, and brain. Exploring the nature and behavior of these potent cells would provide a better understanding of the disease.
The history of cancer stem cells began in the year 1950, when Roy Stevens observed an elevated rate of testicular teratoma in a mice strain 129 [2] . In addition to the testicular teratomas being derived from the three primary germ layers, there were some embryonal carcinoma (EC) cells [3] . Later in 1964, Kleinsmith and Pierce formed the basis of CSC theory by demonstrating that single cell clones of EC cells also have the property of multipotency and pluripotency [4] . The CSC hypothesis was later rediscovered by Bonnet and Dick when they identified that in acute myeloid leukemia, fewer number of (100-fold less) CD34 + CD38
− cells were required to cause leukemic proliferation as opposed to CD34 + CD38 + cells [5] . This led to the concept of CSC markers, wherein a set of markers are found to be characteristic of each CSC type. A population of 100 ESA + CD44
+ CD24 −/low cells were able to form breast tumors rapidly when compared to no tumor formation from as many as 20,000 CD44 + CD24 + cells thereby reinforcing the concept of increased tumorigenic potency of a population of cells decorated by specific cell surface markers [6] (Fig. 1) .
CSCs are also known as cancer-initiating cells, side population (SP) or tumor-initiating cells (TICs). There are several methods employed to isolate these altered stem cells from a heterogeneous population of cancer cells. Two methods using FACS are (1) DNA binding Hoechst dye33342-based exclusion method in which the dye bound cells will be sorted out using flow cytometry. This gives rise to two types of cells-SP and non-side population (NSP). Due to the presence of increased multi-drug transporter proteins (ABCG transporters) in the SP cells, they expel the dye and thus emit low fluorescence when compared to the NSP cells [7, 8] (Fig. 2) and (2) marker-based isolation (Fig. 2) . For example, pancreatic CSCs can be isolated using antibody against CD44 + CD24 + ESA + . Other methods include magnetic cell sorting [9] , ALDEFLUR assay [10] , and in situ detection [10] .
After isolation, these CSCs are enriched in vitro by tumorsphere assays which use low-attachment plates or soft agar assay to select for the anchorage-independent cells-cells which can survive the harsh environment (mammosphere and pancreatosphere assay for breast and pancreatic CSCs, respectively). Further, these cells are tested for their tumorigenic potential in vivo by serial transplantation assays in which cells are injected into NOD-SCID mice either subcutaneously, orthotopically or intraperitoneally, and are allowed to grow for few weeks. These CSCs leads to the formation of larger tumors compared to that of the small/no tumors in the non-CSCs injected region. Therefore, minimal number of CSCs is responsible to recreate the "tumor phenomenon."
Finally, the combination of oncology and stem cell biology has led us to explore this dreadful disease further, i.e., studying cancer with a different perspective which includes novel approaches and it has opened a new challenging concept left partially explored.
Specific markers of CSCs and therapeutic implications
CSCs share the characteristics of normal adult stem cells such as self-renewal, stemness, and drug resistance. One of the hypotheses for CSCs describes that if the adult stem cells gets mutated and is involved in uncontrolled proliferation, it would become the CSC population. The differences between maintenance markers for adult and CSCs are not well understood. However, numerous surface markers were identified which were specifically attributed to CSCs. CSCs were isolated from several cancers such as brain, lung, hepatocellular, breast, ovarian, prostate, head and neck, hematological, and pancreatic cancers (Fig. 1) . The identified cell surface markers are an important target for CSC therapy.
Pancreatic, liver, colorectal, breast, ovarian, and prostate cancer stem cell characterization and its markers are well established in CSC research. Pancreatic cancer is the fourth most common cause of cancer related deaths in the USA, showing worst prognosis of all human cancers and resistant to chemotherapeutic agents. CSCs in pancreatic cancer constitute less than 1 % of the total tumor cell population and express specific surface markers such as CD44 + /CD24 + /ESA/ CD133 + [7] . Furthermore, the isolated pancreatic CSCs also show overexpression of sonic hedgehog (SHH) and polycomb Fig. 1 A schematic representation of cancer stem cell surface markers and its phenomenal characteristics. CSC surface markers are described for several cancers, such as brain, lung, hepatocellular, colorectal, breast, ovarian, prostate, pancreatic, hematological, and head and neck malignancies. The characteristics of CSCs are self-renewal, drug resistance, tumorigenicity, and metastasis group gene family member Bmi-1 gene [11] [12] [13] which are responsible for the maintenance of CSCs. Recent studies have also shown the increased expression of CXC chemokine receptor 4 (CXCR4) in CD133 + pancreatic cancer stem cells [14] . The liver is one of the highly regenerative potential organs which carry oval progenitor cells around the peripheral branches of the bile ducts [15] . The normal liver progenitor cells share molecular markers with hepatocytes (albumin, CK7, and CK19), oval cell markers (OV6, A6, and OV1), and fetal hepatocyte marker (α fetoprotein) and are also positive for common stem cell markers such as CD34 + , Thy-1 + , c-Kit + , and Flt-3 + [16, 17] . In human hepatocellular carcinoma, CD133
+ cells possess the potential to self-renew by expressing Notch, BMI, and Oct3/4 [18, 19] . Colorectal adult stem cells reside at the bottom of the crypt and differentiate into >10 10 new cells daily and mutations even in a single stem cell located at the bottom of the crypt develops colorectal cancer [20] . Colorectal cancer is the third most frequent cancer worldwide and is the second most reason for cancer-related deaths in western countries and it develops more drug resistance and tumor recurrence after chemotherapeutic treatment. CSCs in colon cancer express CD133 + , CD44 + , CD166, CD49f, and ESA markers [20, 21] and these markers can be used to enrich colon CSCs. Breast cancer is one of the major causes of cancer related deaths in women worldwide. Breast CSCs originate from multi-potent stem cells present in the mammary fat pad and genetic mutations and alterations affect self-renewal and differentiation features. The mammary adult stem cells of murine express CD29f + , CD24 + , and Linmarkers [22] [10, 23, 24] . The self-renewal factors for both normal and malignant mammary stem cells are Notch [23] , hedgehog (SHH) [25] , Wnt/β-catenin [26] , epidermal growth factors and receptors (EGF/EGFR) [27] , leukemia inhibitory factor [28] , Oct3/4, ALDH1, and SOX1 [24, 29] . The terminal differentiation of prostate epithelium is Fig. 2 A + for hematological malignancies [32, 33] and CD44 + for head and neck cancer were also established [34] .
Most of the cancers are resistant to chemotherapeutic drugs due to CSC population which ultimately results in tumor relapse and thus decrease the survival of patients [7, 35] . In several recent studies, the activation and upregulation of some specific signaling pathways such as PI3K/Akt/mTOR, hedgehog, HMG-CoA reductase, and Notch were exclusively involved in the CSC population [36] [37] [38] [39] [40] [41] [42] [43] . CD34 in leukemia cells was also strongly correlated with ABC transporter, which plays a role in drug efflux, which can be used as a chemotherapeutic target. CD33 expression is detected in 80-90 % of leukemia cells as well as CSC populations [44, 45] . The antibody against CD33 (gemtuzumab ozogamacin-GO) became an important target for both leukemia cells-and CSCtargeted therapy. Targeting these pathways has been focused on by many researchers. PI3K/Akt/mTOR pathway has been inhibited in renal cell carcinoma using temsirolimus and everolimus. hedgehog inhibitors GDC-0449, PF04449913, BMS833923, and LDE225 were used for solid tumors, colorectal, hematological, basal cell, and meduloblastoma tumors respectively [46] . Notch inhibitors MK0752, RO4929097, PF-03084041 were used for breast, pancreatic, renal cell, and leukemia cancers, respectively [46] . Recent studies explored that HMG-CoA reductase inhibitor plays a role in CSCs. The CSC population is believed to escape from oxidative stress which results in increased survival [41, 47] . The inhibitors of HMG-CoA namely imatinib and simvastatin are showing a synergistic effect in chronic myelogenous leukemia cells [47] . Mesenchymal stem cells (MSCs) are also most widely used adult stem cells for therapeutic applications of several diseases. Recent studies have shown that the effect of MSCs in reduced proliferation and decreased apoptosis in leukemia stem cells [42, 43] . The effective treatment for cancer lies in targeting CSCs with specific molecules or pharmacological inhibitors.
CSCs in drug resistance
Although chemotherapy eradicates most tumor cells, small populations of tumor stem cells which have resistance to cancer therapy are left behind resulting in recurrence of tumor. This resistance is due to the protection imparted by an increased expression of the ATP-binding cassette (ABC) drug transporters [7, 35] . For instance; it was shown that the CD44 + CD24
− breast cancer stem cells had increased ABCG2 mRNA expression when compared to the alternative phenotype [48] . These multi-drug transporters use their drug efflux mechanisms to toss out the drug thereby decreasing the intracellular drug levels and thus being indifferent to the cancer treatment. The ABC transporters constitute the largest transmembrane protein family [49] . This large family is further divided into seven subfamilies which are designated A to G based on their structural and sequence homology [49] . The most challenging research of reversing the multi-drug resistance in these CSCs by inhibiting specific ABC transporters has been carried out for more than two decades [49] . There were three generations of ABCB1 inhibitors designed to be administered along with front line chemotherapy although all of them proved to be a failure and none of them had any additional effect on prognosis. First-generation inhibitors like cyclosporine A and verapamil were approved in the 1980s for non-cancer conditions, unfortunately these inhibitors were found to be highly toxic [49] . Though the second-generation inhibitors such as valspodar were improved in terms of decreased toxicity and increased potency they remained a failure as well since the patient was indifferent to these drugs during a phase III trial [49, 50] . Even the third-generation drugs such as Zosuquidar failed during a phase II trial [51] . Therefore, understanding the underlying mechanisms of stem cell resistance due to these MDR transporters is critical to improve our anticancer strategies and thereby identify new therapeutic targets [35] .
CSCs and metastasis
The successful process of seeding and colonization of CSCs results in distant organ metastasis [52] . From the heterogeneous population of primary tumor cells, only a small fraction moves into circulation and 1/100th fraction of these cells develops into metastases. [53] . These cells are believed to undergo EMT during which their epithelial characteristics are lost thus acquiring invasiveness and stem cell traits [54] . Two major metastasis models have been framed in the breast cancer field. Firstly, the classical model in which metastasis is treated as the final stage of cancer evolution where the tumors acquire several mutations that lead to invasiveness which further leads into dissemination [55] . Secondly, another model was proposed in which metastasis was considered to be an early event which behaves as an inherent property of the tumor itself [56] . Both models prevail but the classical model is considered conceptually flawed as (1) metastatic lesions do appear after resection of small tumors which were not metastatic at diagnosis and (2) unknown primary tumors are metastatic and account for 4-5 % of total clinical metastases [57] .
The second model, however, has been recently proven in pancreatic cancer where it is shown that EMT and dissemination occur before tumor formation [57] . CSCs are found to involve in the process of metastasis. For example, in colorectal cancer when CD26 + CSCs were injected into mice, it progressed into distant metastasis whereas CD26
− cells did not show that phenotype [58] . Similarly, CD133 + CXCR4 + CSCs were found to be responsible for the metastatic phenotype in pancreatic cancer [14] . Identification and careful targeting of this subset of CSCs which have the metastatic capacity would help in fighting against cancer.
CSCs and tumor microenvironment
CSCs that originally underwent mutation in various ways are the chief reason for the development of tumor and its progression. Yet, these CSCs solely cannot lead to malignancy. They require the assistance of an environment which is corrupted as well and is thereby able to support the growth of these altered stem cells or CSCs [59] . Similar to stem cells which requires specific signals to maintain its stem cell nature the CSCs also rely on the microenvironment to maintain its properties [59, 60] . The tumor microenvironment (TME) is made up of several constituents such as (1) cancer cells that undergo dysregulated proliferation; (2) cancer stem cells, which constitutes a minor fraction (<5 %) of the total population of cells; (3) stromal cells consisting of cancer associated fibroblastic cells, infiltrating immune cells, and angiogenic vascular cells [59] ; (4) Extracellular matrix (ECM) components such as laminin, collagen, fibronectin, and elastin; and (5) non-cancer cells [59, 61] . The strong interactions between all these diverse cells, ECM, and various stromal factors in addition to the geometric constraints that a cell undergoes define a TME [62] . TME contributes to tumor escape by activating the intricate molecular mechanisms thereby inhibiting the immune cells to function [63] . In addition to the specialized niche, both the genetic or environmental variations imposed on the cells lead to aberrant signaling, thereby facilitating the production of altered stem cells [64] . Moreover, these aberrant stem cells can lead to EMT promoting tumor metastasis [65] . By understanding the role of different components of the TME, novel therapeutic targets could be used against these potential cells to impede or reduce the tumor growth.
CSCs and pathways
Several pathways that regulate the controlled proliferation of stem cells are found to be disrupted in CSCs. The three most widely studied signaling pathways are Notch, Wnt/ β-catenin, and Sonic hedgehog.
Wnt signaling/Notch/SHH: Wnt/β-catenin signaling is found to play a chief role in the maintenance and homeostasis of stem cells originating from prostate, intestine, breast, pancreatic, ovarian, and brain tumors [7, 26, 66, 67] . Wnt signaling facilitates the entry of β-catenin into the nucleus and interacts with DNA binding proteins and results in repression or/and activation of target gene transcription [26, 66] . In the intestine, Wnt signaling is essential for the maintenance and homeostasis of stem cells [66, 68] . During a cancerous condition, Wnt signaling functions abruptly due to mutations in its key components of the pathway such as a well-known tumor suppressor namely adenomatous polyposis coli (APC) gene that targets β-catenin for degradation [26, 66, 69] . Recent studies showed that in the APC loss-of-function mutant (Apc1322T) mice there was an elevated expression of stem cell markers such as Lgr5, Bmi1, Musashi1, and the Wnt target CD44 (later identified as the colorectal CSC marker) [21, 70] . Further, when CD44 was deleted in APC Min/+ it was found to attenuate intestinal tumorigenesis [71] . Overall, the above studies show that Wnt signaling is found to play an important role in the contribution of tumorigenesis and thus supports the CSC model. Notch-signaling creates paracrine communication between two cells. Notch family members are identified as oncogenes in several malignancies [72, 73] . They are expressed during mammalian development in numerous tissues and are also involved in proliferation, differentiation, and survival of cells [72, 74] . Notch directly plays a role in the formation of definitive hematopoietic stem cells [74] . Notch is one of the signaling pathways which is involved in the maintenance of stem cells and plays an important role in cancer [74, 75] . Recent studies have also demonstrated that Notch inhibitors (MK0752, RO4929097, and PF-03084041) target cancer cells and CSCs [46] .
In mammalian cells, SHH ligands mediate SHH signaling pathways (Pasca di and Hebrok, 2003) . The pathway is activated when the ligand binds to Patched (PTCH1), a 12-pass transmembrane-spanning receptor [76] . The absence of SHH leads to the constitutive repression of a seven-pass transmembrane protein namely Smoothened (SMO) [76] . When the ligand binds to PTCH, SMO is derepressed thus activating the Gli zinc-finger transcription factors such as Gli1, Gli2, and Gli3 [76, 77] . In cancer conditions, the prime reason for the contribution of basal cell carcinoma is due to mutations in PTCH1 and SMO leading to the constitutive activation of SHH signaling [69] . Other mutations such as Gli1 and Gli3 mutations are also observed in pancreatic adenocarcinoma and in glioblastoma, Gli1 gene amplification was seen [76] . In Glioblastoma CSCs, the Hh signaling pathway was found to be active which was inhibited using siRNA based method or using cyclopamine against the components of the pathway thereby reversing the tumorigenesis [78, 79] . In breast cancer, Hh ligands were used to activate the CSC pathway which resulted in GLI1 or GLI2 expression [80, 81] . On inhibiting this pathway using siRNA directed against GLI1 and GLI2 or by using cyclopamine, the expression of BMI-1 (a selfrenewal factor/oncogene) was altered [80, 81] .
Other pathways
Other signaling pathways such as the Polycomb group transcriptional repressor, Bmi-1 was found to be essential for the self-renewal of stem cells in the hematopoietic system, peripheral and central nervous system [82, 83] . It was observed that Bmi-1-deficient neural stem cells had a reduced capacity of self-renewal which led to their postnatal depletion [82] . Depletion of Bmi-1 led to increased β-catenin signaling which led to blockage of the self-renewal activity of p63 + stem cells [84] . Another study showed that on targeting the Bmi-1 in glioma using microRNA-128, both self-renewal and proliferation was inhibited [80] .
To summarize, in CSCs, simple pathways turn complex due to certain alterations in their underlying molecular mechanisms. Thus Wnt, Notch, and SHH signalings control the CSC fate decisions with the assistance of a tumor microenvironment. Therefore, a thorough understanding of these complex pathways is required in order to target and inactivate CSCs.
Future directions
Understanding the critical details in the field of CSCs holds great promise towards the cure of cancer. To eradicate these CSCs, safe targeted therapies should be developed against this small population of transformed stem cells. Greater focus should be imparted towards several areas in CSC research, which has attained partial success such as in areas designing new inhibitors/drugs to inhibit ABC transporters and in areas identifying highly specific markers (both on the surface and within cells) for each cancer type [49, 85] . Although the technical advancements in the CSC field has provided various methods for the isolation, characterization, and have provided the properties of CSCs, their functional properties have not been well evaluated [85, 86] . Further investigations of the behavior of CSCs should be extended even in progressive cancer models. Identification of novel molecules, which plays an important role in the maintenance of CSCs, may serve as therapeutic targets. In the future, effective treatment for cancer requires targeting biomolecules which can eliminate both differentiated cancer cells and the potential CSC populations specific to different cancers.
